CLL	chronic lymphocytic leukemia
MBC	monoclonal B cells
TEMRA	terminally differentiated memory T cells
EM	effector memory T cells
Th	T helper
Tregs	T regulatory cells
NK	natural killer
NKT	natural killer T
M-MDSCs	monocytic myeloid-derived suppressor cells
NLCs	nurse like cells
DCs	dendritic cells
TTFT	time-to-first treatment
OS	overall survival
PFS	progression-free survival
FCR	fludarabine-cyclophosphamide-rituximab
IGHV	immunoglobulin heavy chain variable region
TCR	T cell receptor
MBL	monoclonal B cell lymphocytosis
mAb	monoclonal antibody
ADCC	antibody-dependent cell-mediated-cytotoxicity
KIRs	killer Ig-like receptors
NCRs	natural cytokine receptors
Ig	immunoglobulin
TFS	treatment-free survival
TTP	time to progression
PMN-MDSCs	polymorphonuclear myeloid-derived suppressor cells
AIHA	autoimmune hemolytic anemia
ITP	immune thrombocytopenia
DAT	direct antiglobulin test
SIR	standardized incidence ratio
SEER	surveillance epidemiology and end results
CR	complete remission
LDT	lymphocyte doubling time
TTT	time-to-treatment